Cytokinetics' ispinesib fails NSCLC Phase II

CYTK said results from an interim analysis in the platinum-sensitive arm of a Phase II trial of ispinesib ( SB-715992) to treat non-small cell lung cancer (NSCLC) were not sufficient to proceed to the next stage of the trial. Continuation would have required at least one partial or complete response out of 20 evaluable patients. Last September, CYTK said results from the platinum-refractory arm of the NSCLC trial also were not sufficient to proceed (see BioCentury Extra, Tuesday Sept. 27, 2005). ...